These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 14984270)

  • 21. Drug dissolution from indomethacin-starch hybrid powders prepared by the dry impact blending method.
    Ishizaka T; Honda H; Koishi M
    J Pharm Pharmacol; 1993 Sep; 45(9):770-4. PubMed ID: 7903362
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of geometric factors on hydration kinetics of theophylline anhydrate tablets.
    Otsuka M; Kaneniwa N; Otsuka K; Kawakami K; Umezawa O; Matsuda Y
    J Pharm Sci; 1992 Dec; 81(12):1189-93. PubMed ID: 1491338
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Better understanding of dissolution behaviour of amorphous drugs by in situ solid-state analysis using Raman spectroscopy.
    Savolainen M; Kogermann K; Heinz A; Aaltonen J; Peltonen L; Strachan C; Yliruusi J
    Eur J Pharm Biopharm; 2009 Jan; 71(1):71-9. PubMed ID: 18590816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preparation and characterization of multi-component tablets containing co-amorphous salts: Combining multimodal non-linear optical imaging with established analytical methods.
    Ojarinta R; Saarinen J; Strachan CJ; Korhonen O; Laitinen R
    Eur J Pharm Biopharm; 2018 Nov; 132():112-126. PubMed ID: 30248394
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dextrose monohydrate as a non-animal sourced alternative diluent in high shear wet granulation tablet formulations.
    Mitra B; Wolfe C; Wu SJ
    Drug Dev Ind Pharm; 2018 May; 44(5):817-828. PubMed ID: 29300107
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dissolution of theophylline monohydrate and anhydrous theophylline in buffer solutions.
    de Smidt JH; Fokkens JG; Grijseels H; Crommelin DJ
    J Pharm Sci; 1986 May; 75(5):497-501. PubMed ID: 3735090
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Investigation of excipient and processing on solid phase transformation and dissolution of ciprofloxacin.
    Li X; Zhi F; Hu Y
    Int J Pharm; 2007 Jan; 328(2):177-82. PubMed ID: 16978809
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Simultaneous measurement of liquid-phase and solid-phase transformation kinetics in rotating disc and channel flow cell dissolution devices.
    Lehto P; Aaltonen J; Niemelä P; Rantanen J; Hirvonen J; Tanninen VP; Peltonen L
    Int J Pharm; 2008 Nov; 363(1-2):66-72. PubMed ID: 18675891
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of moisture on the physical stability of polymorphic olanzapine.
    Paisana MC; Wahl MA; Pinto JF
    Int J Pharm; 2016 Jul; 509(1-2):135-148. PubMed ID: 27234701
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative determination of polymorphs of indomethacin in powders and tablets by chemometrical near-infrared spectroscopy and x-ray powder diffractometry.
    Otsuka M; Kato F; Matsuda Y; Ozaki Y
    AAPS PharmSciTech; 2003; 4(2):E19. PubMed ID: 12916901
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantification, mechanism, and mitigation of active ingredient phase transformation in tablets.
    Thakral NK; Ragoonanan V; Suryanarayanan R
    Mol Pharm; 2013 Aug; 10(8):3128-36. PubMed ID: 23869937
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Depth profiling of compression-induced disorders and polymorphic transition on tablet surfaces with grazing incidence X-ray diffraction.
    Koivisto M; Heinänen P; Tanninen VP; Lehto VP
    Pharm Res; 2006 Apr; 23(4):813-20. PubMed ID: 16463008
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simultaneous UV imaging and raman spectroscopy for the measurement of solvent-mediated phase transformations during dissolution testing.
    Østergaard J; Wu JX; Naelapää K; Boetker JP; Jensen H; Rantanen J
    J Pharm Sci; 2014 Apr; 103(4):1149-56. PubMed ID: 24496995
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of surface- and nano-crystallisation on the detected amorphous content and the dissolution behaviour of amorphous indomethacin.
    Priemel PA; Grohganz H; Gordon KC; Rades T; Strachan CJ
    Eur J Pharm Biopharm; 2012 Sep; 82(1):187-93. PubMed ID: 22683936
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Understanding the behavior of amorphous pharmaceutical systems during dissolution.
    Alonzo DE; Zhang GG; Zhou D; Gao Y; Taylor LS
    Pharm Res; 2010 Apr; 27(4):608-18. PubMed ID: 20151181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Theophylline-nicotinamide cocrystal formation in physical mixture during storage.
    Ervasti T; Aaltonen J; Ketolainen J
    Int J Pharm; 2015; 486(1-2):121-30. PubMed ID: 25800677
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In situ amorphisation of indomethacin with Eudragit® E during dissolution.
    Priemel PA; Laitinen R; Grohganz H; Rades T; Strachan CJ
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1259-65. PubMed ID: 24056054
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Salt formation during freeze-drying--an approach to enhance indomethacin dissolution.
    Thakral S; Suryanarayanan R
    Pharm Res; 2015 Nov; 32(11):3722-31. PubMed ID: 26063046
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Polymorphic Transformation of Indomethacin during Hot Melt Extrusion Granulation: Process and Dissolution Control.
    Xu T; Nahar K; Dave R; Bates S; Morris K
    Pharm Res; 2018 May; 35(7):140. PubMed ID: 29748722
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of tableting pressure on hydration kinetics of theophylline anhydrate tablets.
    Otsuka M; Kaneniwa N; Kawakami K; Umezawa O
    J Pharm Pharmacol; 1991 Apr; 43(4):226-31. PubMed ID: 1676732
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.